BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 14689587)

  • 1. Bone morphogenetic protein signaling in prostate cancer cell lines.
    Brubaker KD; Corey E; Brown LG; Vessella RL
    J Cell Biochem; 2004 Jan; 91(1):151-60. PubMed ID: 14689587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone morphogenetic protein-2 induces hypophosphorylation of Rb protein and repression of E2F in androgen-treated LNCaP human prostate cancer cells.
    Tomari K; Kumagai T; Shimizu T; Takeda K
    Int J Mol Med; 2005 Feb; 15(2):253-8. PubMed ID: 15647840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer.
    Feeley BT; Gamradt SC; Hsu WK; Liu N; Krenek L; Robbins P; Huard J; Lieberman JR
    J Bone Miner Res; 2005 Dec; 20(12):2189-99. PubMed ID: 16294272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions.
    Feeley BT; Krenek L; Liu N; Hsu WK; Gamradt SC; Schwarz EM; Huard J; Lieberman JR
    Bone; 2006 Feb; 38(2):154-66. PubMed ID: 16126463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone morphogenetic protein-2 blocks MDA MB 231 human breast cancer cell proliferation by inhibiting cyclin-dependent kinase-mediated retinoblastoma protein phosphorylation.
    Ghosh-Choudhury N; Woodruff K; Qi W; Celeste A; Abboud SL; Ghosh Choudhury G
    Biochem Biophys Res Commun; 2000 Jun; 272(3):705-11. PubMed ID: 10860819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro.
    Lin DL; Tarnowski CP; Zhang J; Dai J; Rohn E; Patel AH; Morris MD; Keller ET
    Prostate; 2001 May; 47(3):212-21. PubMed ID: 11351351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BMP signals inhibit proliferation and in vivo tumor growth of androgen-insensitive prostate carcinoma cells.
    Miyazaki H; Watabe T; Kitamura T; Miyazono K
    Oncogene; 2004 Dec; 23(58):9326-35. PubMed ID: 15531927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteoprotegerin in prostate cancer bone metastasis.
    Corey E; Brown LG; Kiefer JA; Quinn JE; Pitts TE; Blair JM; Vessella RL
    Cancer Res; 2005 Mar; 65(5):1710-8. PubMed ID: 15753366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice.
    Yonou H; Kanomata N; Goya M; Kamijo T; Yokose T; Hasebe T; Nagai K; Hatano T; Ogawa Y; Ochiai A
    Cancer Res; 2003 May; 63(9):2096-102. PubMed ID: 12727825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dissociation of bone morphogenetic protein-mediated growth arrest and apoptosis of mouse B cells by HPV-16 E6/E7.
    Yamato K; Hashimoto S; Okahashi N; Ishisaki A; Nonaka K; Koseki T; Kizaki M; Ikeda Y; Nishihara T
    Exp Cell Res; 2000 May; 257(1):198-205. PubMed ID: 10854068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapamycin induces Smad activity in prostate cancer cell lines.
    van der Poel HG; Hanrahan C; Zhong H; Simons JW
    Urol Res; 2003 Feb; 30(6):380-6. PubMed ID: 12599018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism.
    Dai J; Keller J; Zhang J; Lu Y; Yao Z; Keller ET
    Cancer Res; 2005 Sep; 65(18):8274-85. PubMed ID: 16166304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growth regulation of human prostate cancer cells by bone morphogenetic protein-2.
    Ide H; Yoshida T; Matsumoto N; Aoki K; Osada Y; Sugimura T; Terada M
    Cancer Res; 1997 Nov; 57(22):5022-7. PubMed ID: 9371496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Down-regulation of neu/HER-2 by interferon-gamma in prostate cancer cells.
    Kominsky SL; Hobeika AC; Lake FA; Torres BA; Johnson HM
    Cancer Res; 2000 Jul; 60(14):3904-8. PubMed ID: 10919667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BMP-2 modulates the proliferation and differentiation of normal and cancerous gastric cells.
    Wen XZ; Miyake S; Akiyama Y; Yuasa Y
    Biochem Biophys Res Commun; 2004 Mar; 316(1):100-6. PubMed ID: 15003517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone morphogenetic protein (BMP) ligands and receptors in bovine ovarian follicle cells: actions of BMP-4, -6 and -7 on granulosa cells and differential modulation of Smad-1 phosphorylation by follistatin.
    Glister C; Kemp CF; Knight PG
    Reproduction; 2004 Feb; 127(2):239-54. PubMed ID: 15056790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Up-regulation of p21(WAF1/CIP1) levels leads to growth suppression of prostate cancer cell lines.
    Sugibayashi R; Kiguchi Y; Shimizu T; Suzuki T; Hamada H; Takeda K
    Anticancer Res; 2002; 22(2A):713-9. PubMed ID: 12014641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone morphogenetic protein (BMP)-6 signaling and BMP antagonist noggin in prostate cancer.
    Haudenschild DR; Palmer SM; Moseley TA; You Z; Reddi AH
    Cancer Res; 2004 Nov; 64(22):8276-84. PubMed ID: 15548695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone morphogenetic protein-9 induces apoptosis in prostate cancer cells, the role of prostate apoptosis response-4.
    Ye L; Kynaston H; Jiang WG
    Mol Cancer Res; 2008 Oct; 6(10):1594-606. PubMed ID: 18922975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
    Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
    Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.